To probe the functional differences of short WDFY2 versus wildtype WDFY2 on signaling pathways, we performed reverse phase protein arrays (RPPA) [16], which provides a means to quantitatively assess the levels of 130 cancer-associated proteins using 163 distinct antibodies. This evidence concerns the gene WDFY2 and cancer.